KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Operations (2016 - 2025)

Rigel Pharmaceuticals has reported Cash from Operations over the past 16 years, most recently at 21980000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 21980000.0 for Q4 2025, up 51.55% from a year ago — trailing twelve months through Dec 2025 was 75655000.0 (up 140.4% YoY), and the annual figure for FY2025 was 75655000.0, up 140.4%.
  • Cash from Operations for Q4 2025 was 21980000.0 at Rigel Pharmaceuticals, down from 24031000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for RIGL hit a ceiling of 55216000.0 in Q2 2021 and a floor of 25637000.0 in Q1 2022.
  • Median Cash from Operations over the past 5 years was 2716500.0 (2023), compared with a mean of 1675150.0.
  • Biggest five-year swings in Cash from Operations: crashed 545.17% in 2021 and later surged 10011.59% in 2025.
  • Rigel Pharmaceuticals' Cash from Operations stood at 19086000.0 in 2021, then decreased by 14.79% to 21909000.0 in 2022, then soared by 71.52% to 6240000.0 in 2023, then skyrocketed by 332.42% to 14503000.0 in 2024, then surged by 51.55% to 21980000.0 in 2025.
  • The last three reported values for Cash from Operations were 21980000.0 (Q4 2025), 24031000.0 (Q3 2025), and 30537000.0 (Q2 2025) per Business Quant data.